90 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
12 Apr 24
Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader sarcoma franchise
8:05am
collaboration with our partner Genentech, and we continue to believe in the long-term potential of our iPSC-based allogeneic platform. Over the past
8-K
EX-99.1
uw0yeje2 m4
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.4
1hnhr6
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
nyf 20gibvm
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.3
7zyhz g9mbjh
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
425
9elds6x y694vc4vfi
30 May 23
Business combination disclosure
4:21pm
8-K
eam74evz bg
30 May 23
Submission of Matters to a Vote of Security Holders
4:18pm
425
q7e4i60z w90rh
22 May 23
Business combination disclosure
7:01am
8-K
l3uvvi8d
22 May 23
Other Events
6:59am
8-K
EX-99.1
wx58ajez d29aq14nbs
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
424B3
7vgqr9ivs6rk
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
i0warz
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm